ATR · AptarGroup
AI read · Good for ATR
The AI's read
Broad demand across the business points to growth, with pharma expected to lead the next quarter. The company's expected increase in Q4 profit per share, helped by improved efficiency, supports this read, though it is a forecast, not a completed result. Emergency medicine destocking still weighs on sales, and North American Beauty margins need improvement. Those concerns temper the picture, but growth across all 3 segments and current-quarter profit favor AptarGroup.